Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: An NPR-C-mediated effect

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 6 54-6, 2003, Pages

  Rose, R A ^a   Lomax, A E ^a   Giles, W R ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Action potential; C receptor; Heart

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL L TYPE; CANF; GUANYLATE CYCLASE; HS 142 1; ISOPRENALINE; NATRIURETIC PEPTIDE C RECEPTOR; NATRIURETIC PEPTIDE C TYPE; POTASSIUM ION; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BULLFROG; CALCIUM CURRENT; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; HEART ATRIUM; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; VOLTAGE CLAMP;

EID: 0344708481     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00388.2003     Document Type: Article

References (63)

1. Anand-Srivastava MB and Cantin M. Atrial natriuretic factor receptors are negatively coupled to adenylate cyclase in cultured atrial and ventricular cardiocytes. Biochem Biophys Res Commun 138: 427-436, 198
2. Anand-Srivastava MB, Sairam MR, and Cantin M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. J Biol Chem 265: 8566-8572, 1990.
3. Anand-Srivastava MB, Sehl PD, and Lowe DG. Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. J Biol Chem 271: 19324-19329, 1996.
4. Anand-Srivastava MB, Srivastava AK, and Cantin M. Pertussis toxin attenuates atrial natriuretic factor-mediated inhibition of adenylate cyclase. J Biol Chem 262: 4391-4394, 1987.
5. Anand-Srivastava MB and Trachte GJ. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 45: 455-497, 1993.
6. Barr CS, Rhodes P, and Struthers AD. C-type natriuretic peptide. Peptides 17: 1243-1251, 1996.
7. Bers DM and Ziolo MT. When is cAMP not cAMP? Effects of compartmentalization. Circ Res 89: 373-375, 2001.
8. Brown JH. Cholinergic inhibition of catecholamine-stimulable cyclic AMP accumulation in murine atria. J Cyclic Nucleotide Res 5: 423-433, 1979.
9. Brown JH. Depolarization-induced inhibition of cyclic AMP accumulation: cholinergic-adrenergic antagonism in murine atria. Mol Pharmacol 16: 841-850, 1979.
10. Campbell DL, Giles WR, and Shibata EF. Ion transfer characteristics of the calcium current in bull-frog atrial myocytes. J Physiol 403: 239-266, 1988.
11. Chauhan S, Nilsson H, Ahluwalia A, and Hobbs A. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 100: 1426-1431, 2003.
12. Chen HH and Burnett Jr JC. C-type natriuretic peptide: The endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 32: S22-S28, 1998.
13. Clark RB and Giles WR. Sodium current in single cells from bullfrog atrium: voltage dependence and ion transfer properties. J Physiol 391: 235-265, 1987.
14. Crilley JG and Farrer M. Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 86: 638-642, 2001.
15. Darbar D, Davidson NC, Gillespie N, Choy AJ, Lang CC, Shyr Y, McNeill GP, Pringle TH, and Struthers AD. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 78: 284-287, 1996.
16. De Bold AJ, Borenstein HB, Veress AT, and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 28: 89-94, 1981.
17. Doyle DD, Upshaw-Earley J, Bell EL, and Palfrey HC. Natriuretic peptide receptor-B in adult rat ventricle is predominantly confined to the nonmyocyte poplulation. Am J Physiol Heart Circ Physiol 282: H2117-H2123, 2002.
18. Fischmeister R and Hartzell HC. Mechanism of action of acetylcholine on calcium current in single cells from frog ventricle. J Physiol 376: 183-202, 1986.
19. Flynn TG, de Bold ML, and de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117: 859-865, 1983.
20. Giles W and Noble SJ. Changes in membrane currents in bullfrog atrium produced by acetylcholine. J Physiol 261: 103-123, 1976.
21. Gisbert MP and Fischmeister R. Atrial natriuretic factor regulates the calcium current in frog isolated cardiac cells. Circ Res 62: 660-667, 1988.
22. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391: 85-100, 1981.
23. Hanoune J and Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41: 145-174, 2001.
24. He X, Chow D, Martick MM, and Garcia KC. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science 293: 1657-1662, 2001.
25. Herring N, Zaman JAB, and Paterson DJ. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol 281: H2318-H2327, 2001.
26. Herzig S and Neuman J. Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Pharmacol Rev 80: 173-210, 2000.
27. Hiraoka H. Modulation of electrical properties by ions, hormones and drugs. Handbook of Physiology. The Cardiovascular System. The Heart. Bethesda, MD: Am. Physiol. Soc., 2002, sect. 2, vol. 1, p. 595-653.
28. Hirose M, Furukawa Y, Kurogouchi F, Nakajima K, Miyashita Y, and Chiba S. C-type natriuretic peptide increases myocardail contractility and sinus rate mediated by guanyly cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Exp Ther 286: 70-76, 1998.
29. Hove-Madsen L, Mery PF, Jurevicius J, Skeberdis A, and Fischmeister R. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res Cardiol 91, Suppl 2: 1-8, 1996.
30. Hume JR and Giles W. Ionic currents in single isolated bullfrog atrial cells. J Gen Physiol 81: 153-194, 1983.
31. Hume JR and Giles WR. Active and passive electrical properties of single bullfrog atrail cells. J Gen Physiol 78: 19-42, 1981.
32. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Yamamuro M, Harada M, Saito Y, Nakao K, Kurihara H, Yasue H, and Ogawa H. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 107: 807-810, 2003.
33. + current in human atrial cells. Pflügers Arch 421: 486-491, 1992.
34. Lee SJ, Kim SZ, Cui X, Kim SH, Lee KS, Chung YJ, and Cho KW. C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling. Am J Physiol Heart Circ Physiol 278: H208-H221, 2000.
35. Levin ER. Natriuretic peptide C-receptor: more than a clearance receptor. Am J Physiol Endocrinol Metab 264: E483-E489, 1993.
36. Levin ER, Gardner DG, and Samson WK. Natriuretic peptides. N Engl J Med 339: 321-328, 1998.
37. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 54: 11-27, 1992.
38. Maack T, Suzuki M, Almeida FA, Nussenzveig O, Scarborough RM, McEnroe GA, and Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 1987.
39. Matsuda Y and Morishita Y. HS-142-1: a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin. Cardiovasc Drug Rev 11: 45-59, 1993.
40. Matsuda Y. Design and utilization of natriuretic peptide antagonists. In: Contemporary Endocrinology: Natriuretic Peptides in Health and Disease, edited by Samson WK and Levin ER. Totowa, NJ: Humana, 1997, p. 289-307.
41. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, and Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88: 82-91, 1993.
42. Murthy KS and Makhlouf GM. Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem 274: 17587-17592, 1999.
43. 1-2-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am J Physiol Gastrointest Liver Physiol 278: G974-G980, 2000.
44. Nakajima T, Wu S, Irisawa H, and Giles W. Mechanism of acetylcholine-induced inhibition of Ca current in bullfrog atrial myocytes. J Gen Physiol 96: 865-885, 1990.
45. Nir A, Zhang DF, Fixler R, BurnettJC Jr, Eilam Y, and Hasin Y. C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol 412: 195-201, 2001.
46. Nunez D, Dickson M, and Brown M. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest 90: 1966-1971, 1992.
47. Ogawa Y, Nakao K, Nakagawa O, Komatsu Y, Hosoda K, Suga S, Arai H, Nagata K, Yoshida N, and Imura H. Human C-type natriuretic peptide: characterization of the gene and peptide. Hypertension 19: 809-813, 1992.
48. 2-adrenergic receptors based on characteristics in primary structure. J Biol Chem 267: 8342-8346, 1992.
49. Omland T, Aakvaag A, Bonarjee WS, Caidahl K, Lie RT, Nilsen DWT, Sundsfjord JA, and Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation 93: 1963-1969, 1996.
50. Ono K and Giles WR. Electrophysiological effects of calcitonin gene-related peptide in bull-frog and guinea-pig atrial myocytes. J Physiol 436: 195-217, 1991.
51. i activator sequences that inhibit adenylyl cyclase activity. J Biol Chem 276: 22064-22070, 2001.
52. Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Frampton C, Crozier IG, and Smyth DW. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 81: 114-120, 1999.
53. Rosenkranz A, Woods R, Dusting G, and Ritchie R. Anti-hypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 57: 515-522, 2003.
54. Taussig R, Tang WJ, Hepler JR, and Gilman AG. Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. J Biol Chem 269: 6093-6100, 1994.
55. 2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 114: 1076-1082, 1995.
56. Trachte GJ. Depeletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux. J Pharmacol Exp Ther 294: 210-215, 2000.
57. Uchiyama M, Murayama T, Matsuda K, Watanabe TX, and Takei Y. Effects of homologous atrial, brain, and c-type natriuretic peptides on isolated heart and blood vessels of bullfrog. Zool Sci 14: 843-847, 1997.
58. Vollmar A, Gerbes A, Nemer M, and Schulz R. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 132: 1872-1874, 1993.
59. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CGA, Edwards WD, Schaff HV, and Burnett Jr JC. Natriuretic peptide system in human heart failure. Circulation 88: 1004-1009, 1993.
60. + channels in the negative chronotropic effect of a muscarinic agonist. J Pharmacol Exp Ther 300: 681-687, 2003.
61. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 235: 561-576, 1994.
62. Yoshihara A, Kozawa H, Minamino N, Kangawa K, and Matsuo H. Isolation and sequence determination of frog C-type natriuretic peptide. Biochem Biophys Res Commun 173: 591-598, 1990.
63. Zhou H and Murthy KS. Identification of the G protein-activating sequence of teh single-transmembrane natriuretic peptide receptor C (NPR-C). Am J Physiol Cell Physiol 284: C1255-C1261, 2003.